Genflow Biosciences annual stock-based compensation
2021
2022
2023
2024
2025
Genflow Biosciences Stock-Based Compensation Growth & History (GENF)
Genflow Biosciences's stock-based compensation was £0 for fiscal 2025.
View full Genflow Biosciences company overviewGenflow Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £0 | £0 | — |
| 2024 | 2024-12-31 | £0 | £0 | — |
| 2023 | 2023-12-31 | £0 | −£72,000 | — |
| 2022 | 2022-12-31 | £72,000 | £53,040 | +279.75% |
| 2021 | 2021-12-31 | £18,960 | — | — |
Genflow Biosciences stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Genflow Biosciences's stock-based compensation decreased from £18,960 to £0, a change of −£18,960.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genflow Biosciences source filings ↗